CaveoVasc System - a New Femoral Vascular Access and Closure Device

Inclusion Criteria: * Age ≥18 years * Patients eligible for a non-emergent diagnostic or interventional catheterization via a femoral sheath of less or equal 6Fr * In the investigator's opinion, the patient is suitable for the CaveoVasc® System , conventional hemostasis techniques and participation in an investigational trial. * Understand and sign the study specific written informed consent form. Exclusion Criteria: * Patients with significant anemia (hemoglobin \<10g/DL, Hct\<30). * Patients with a baseline INR \> 1.5 * Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance \< 30 mL/min, platelets count \< 100,000 mm3), patients with chronic use of vitamin K antagonists, direct thrombin inhibitors or oral factor Xa antagonists * Severe concomitant disease with life expectancy below 12 months * Uncontrolled systemic hypertension * Patients who are immunocompromised. * Patients who need a puncture needle longer than 8 cm due to morbidity obesity * Active systemic or cutaneous infection or inflammation * Prior arterial surgery in abdomen and/or lower extremities * Cardiogenic shock * Patients who are known to be pregnant or lactating. * Patients having a complication(s) at the femoral artery access site pre-sheath removal including hematoma, pseudoaneurysm, or arterio-venous fistula. * Prior femoral vascular surgery or vascular graft in region of access site. * Documented chronic peripheral arterial insufficiency preventing the use of the femoral technique * Patients who are currently participating in another clinical trial of an investigational drug or device that has not concluded the follow-up period. * Patients with known allergy to components of the device. * Patients who cannot adhere to or complete the investigational protocol for any reason